NO135828B - - Google Patents
Download PDFInfo
- Publication number
- NO135828B NO135828B NO1275/72A NO127572A NO135828B NO 135828 B NO135828 B NO 135828B NO 1275/72 A NO1275/72 A NO 1275/72A NO 127572 A NO127572 A NO 127572A NO 135828 B NO135828 B NO 135828B
- Authority
- NO
- Norway
- Prior art keywords
- estradiol
- skin
- day
- effect
- action
- Prior art date
Links
- 229960005309 estradiol Drugs 0.000 claims description 26
- 229930182833 estradiol Natural products 0.000 claims description 15
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 14
- 230000009471 action Effects 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 210000004400 mucous membrane Anatomy 0.000 claims description 8
- 230000000699 topical effect Effects 0.000 claims description 8
- 150000004703 alkoxides Chemical class 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- -1 alkyl sulphate Chemical compound 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 230000003054 hormonal effect Effects 0.000 claims description 3
- 231100000508 hormonal effect Toxicity 0.000 claims description 3
- 150000001347 alkyl bromides Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 210000004209 hair Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 17
- 230000007423 decrease Effects 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 230000001076 estrogenic effect Effects 0.000 description 6
- 229960003604 testosterone Drugs 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 230000012173 estrus Effects 0.000 description 5
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 4
- 206010039792 Seborrhoea Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 229960002568 ethinylestradiol Drugs 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 102000001307 androgen receptors Human genes 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- HLCRYAZDZCJZFG-BDXSIMOUSA-N (8s,9s,13s,14s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene Chemical compound C1CC2=CC=CC=C2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 HLCRYAZDZCJZFG-BDXSIMOUSA-N 0.000 description 1
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical class CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- HNKHISDZGZYDDU-WFEUEMSSSA-N COC1CC2CC=C3C4=CC=C[C@@]4(C)CC[C@@H]3[C@H]2CC1 Chemical compound COC1CC2CC=C3C4=CC=C[C@@]4(C)CC[C@@H]3[C@H]2CC1 HNKHISDZGZYDDU-WFEUEMSSSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001135 feminizing effect Effects 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002488 pyknotic effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- AAAQKTZKLRYKHR-UHFFFAOYSA-N triphenylmethane Chemical compound C1=CC=CC=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 AAAQKTZKLRYKHR-UHFFFAOYSA-N 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/008—Preparations for oily hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1049671 | 1971-04-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO135828B true NO135828B (pt) | 1977-02-28 |
| NO135828C NO135828C (pt) | 1977-06-08 |
Family
ID=9968924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO1275/72A NO135828C (pt) | 1971-04-21 | 1972-04-13 |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS511711B1 (pt) |
| AR (1) | AR193726A1 (pt) |
| AT (1) | AT320873B (pt) |
| AU (1) | AU449978B2 (pt) |
| BE (1) | BE780488A (pt) |
| BR (1) | BR7202453D0 (pt) |
| CA (1) | CA969928A (pt) |
| CH (1) | CH537911A (pt) |
| DE (1) | DE2215499C2 (pt) |
| DK (1) | DK128736B (pt) |
| FR (1) | FR2133579B1 (pt) |
| GB (1) | GB1337198A (pt) |
| IE (1) | IE36277B1 (pt) |
| IL (1) | IL39090A (pt) |
| LU (1) | LU64959A1 (pt) |
| NL (1) | NL154514B (pt) |
| NO (1) | NO135828C (pt) |
| PH (1) | PH14937A (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2350315C2 (de) * | 1973-10-06 | 1984-01-12 | Johnson & Johnson GmbH, 4000 Düsseldorf | Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung |
| NL7800762A (nl) * | 1978-01-20 | 1979-07-24 | Acf Chemiefarma Nv | Vloeibare, voor injectie geschikte farmaceu- tische samenstellingen. |
| CN110003298B (zh) * | 2019-03-22 | 2021-04-27 | 中国人民解放军军事科学院防化研究院 | 一种普罗雌烯的合成方法 |
| CN113480588A (zh) * | 2021-06-16 | 2021-10-08 | 南雄阳普医疗科技有限公司 | 一种甲丙雌二醚的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE17572C (de) * | C. poppenhusen in Hamburg | Verfahren und Apparate zur Herstellung von Bürsten | ||
| DE3C (de) * | 1877-07-03 | H. ZWINGENBERGER zu Ernstthal bei Chemnitz | Einrichtung von Rundwirkmaschinen zur Herstellung von Prefsmustern |
-
1971
- 1971-04-21 GB GB1049671*[A patent/GB1337198A/en not_active Expired
-
1972
- 1972-03-10 BE BE780488A patent/BE780488A/xx not_active IP Right Cessation
- 1972-03-14 LU LU64959D patent/LU64959A1/xx unknown
- 1972-03-15 FR FR7208927A patent/FR2133579B1/fr not_active Expired
- 1972-03-16 CH CH406572A patent/CH537911A/fr not_active IP Right Cessation
- 1972-03-27 IL IL39090A patent/IL39090A/en unknown
- 1972-03-29 DE DE2215499A patent/DE2215499C2/de not_active Expired
- 1972-04-05 JP JP47034301A patent/JPS511711B1/ja active Pending
- 1972-04-06 CA CA139,098A patent/CA969928A/en not_active Expired
- 1972-04-11 NL NL727204812A patent/NL154514B/xx not_active IP Right Cessation
- 1972-04-11 IE IE472/72A patent/IE36277B1/xx unknown
- 1972-04-12 DK DK176972AA patent/DK128736B/da not_active IP Right Cessation
- 1972-04-12 AU AU41045/72A patent/AU449978B2/en not_active Expired
- 1972-04-13 NO NO1275/72A patent/NO135828C/no unknown
- 1972-04-19 PH PH13465A patent/PH14937A/en unknown
- 1972-04-20 BR BR2453/72A patent/BR7202453D0/pt unknown
- 1972-04-21 AR AR241612A patent/AR193726A1/es active
- 1972-04-21 AT AT355172A patent/AT320873B/de active
Also Published As
| Publication number | Publication date |
|---|---|
| AU4104572A (en) | 1973-10-18 |
| IE36277L (en) | 1972-10-21 |
| LU64959A1 (pt) | 1972-07-10 |
| FR2133579B1 (pt) | 1975-02-07 |
| DK128736B (da) | 1974-06-24 |
| BE780488A (fr) | 1972-07-03 |
| CA969928A (en) | 1975-06-24 |
| IE36277B1 (en) | 1976-09-29 |
| IL39090A0 (en) | 1972-05-30 |
| AR193726A1 (es) | 1973-05-22 |
| NO135828C (pt) | 1977-06-08 |
| AU449978B2 (en) | 1974-06-10 |
| NL7204821A (pt) | 1972-10-24 |
| FR2133579A1 (pt) | 1972-12-01 |
| CH537911A (fr) | 1973-06-15 |
| DE2215499C2 (de) | 1974-03-21 |
| IL39090A (en) | 1976-12-31 |
| BR7202453D0 (pt) | 1973-07-17 |
| JPS511711B1 (pt) | 1976-01-20 |
| DE2215499B1 (de) | 1973-08-23 |
| NL154514B (nl) | 1977-09-15 |
| GB1337198A (en) | 1973-11-14 |
| PH14937A (en) | 1982-01-29 |
| AT320873B (de) | 1975-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Austin | Fate of spermatozoa in the uterus of the mouse and rat | |
| RU2166509C2 (ru) | Производные 19-норпрегнена, фармацевтическая композиция, соединения | |
| Smith et al. | The effect of hypophysectomy on ovulation and corpus luteum formation in the rabbit | |
| BG99178A (bg) | Контрацептивен метод,използващ конкурентни прогестеронови антагонисти,и нови съединения,подходящи за приложението му | |
| KR100243537B1 (ko) | 에스트라-1,3,5(10)-트리엔 유도체를 함유한 약제학적 조성물 | |
| Reifenstein et al. | Effect of methyl testosterone on urinary 17-ketosteroids of adrenal origin | |
| Parkes et al. | Interruption of Early Pregnancy by Orally Active Oestrogens | |
| Ferin | A new substance with progestational activity | |
| JP3040175B2 (ja) | １，３，５（１０）−エストラトリエン誘導体のスルファメート誘導体、それらの製造法およびそれらを含有する医薬化合物 | |
| Hartman et al. | The anterior lobe and menstruation | |
| Madjerek et al. | Allylestrenol, a pregnancy maintaining oral gestagen | |
| JP6691193B2 (ja) | プロゲステロン受容体アンタゴニスト剤形 | |
| Nathanson et al. | Nature of the action of testosterone on genital tract of the immature female rat. | |
| NO135828B (pt) | ||
| NO324357B1 (no) | Anvendelse av et ostroprogestagenhormonpreparat ved fremstillingen av et medikament for behandling av ostrogenforstyrrelser og osteoporose hos postmenopausale kvinner, samt anvendelse av et farmasoytisk preparat ved fremstilling av et medikament for a stoppe ovulasjon | |
| RU2364411C1 (ru) | Средство и способ профилактики рецидива кист яичников | |
| ROGERS et al. | Isolation of pregnanediol from human bile after oral administration of progesterone | |
| Robertson et al. | OVAEIAN HORMONE EFFECTS IN OVARIECTOMIZED MONKEYS | |
| US4053489A (en) | Oestratriene diethers | |
| Ben-Nun et al. | Induction of artificial endometrial cycles with oestradiol implants and injectable progesterone: establishment of a viable pregnancy in a woman with 17-a-hydroxylase deficiency | |
| Kubli-Garfias | Modulatory action of 5-reduced androgens and progestins on the excitability of CNS and smooth muscle | |
| UA113283C2 (xx) | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| SALHANICK et al. | BIOLOGICAL ACTIVITY OF 17-α-HYDR0XYPROGESTERONE IN THE MOUSE, RABBIT AND HUMAN BEING | |
| Corner | Corpus luteum therapy | |
| FRANK et al. | Clinical and laboratory investigations of some of the newer sex hormone preparations |